Home Alzheimer’s Disease Advanced Clear Cell RCC Has Favorable Response to Belzutifan/Cabozantinib, Early Findings Show

Advanced Clear Cell RCC Has Favorable Response to Belzutifan/Cabozantinib, Early Findings Show

Disease control was experienced by 90% of patients with previously treated advanced clear cell renal cell carcinoma (ccRCC) who were treated with belzutifan (MK-6482) in combination with cabozantinib (Cabometyx), according to data from an ongoing phase 2 trial (NCT03634540).

Lead author Toni K. Choueiri, MD, presented early findings from a cohort of 52 patients treated with belzutifan, an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, plus cabozantinib at the 2021 Genitourinary Cancers Symposium. He cautioned that the results looked favorable but were very preliminary.1

“These preliminary, interim results for the combination of belzutifan and cabozantinib showed promising activity in previously treated metastatic clear cell RCC,” said Choueiri, director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI)/Brigham and Women’s Hospital…

Continue Reading to the Source


Please enter your comment!
Please enter your name here

Most Popular

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Treatment with PARP Inhibitors Increased Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia

Patients treated with PARP inhibitors saw an increased risk of myelodysplastic syndrome and acute myeloid leukemia (AML) versus patients treated with placebo, according to...

Salma Jabbour, MD, on Next Steps for the KEYNOTE-799 Study

The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed how she hopes the results of the KEYNOTE-799 study...

Recent Comments